Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn ’s Disease Patients
Conclusions: We concluded that IL-6 may be used as a predictive factor to assess the risk of PNR to IFX therapy.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research